ABSTRACT
The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigma I receptor. The present application is further directed, in part, to methods for treating and/or preventing cancer using compounds disclosed herein, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof.
To read the full Patent, click HERE.
Date of publication: 29 October 2020;
Inventor Information: Felix Kim; Joseph Salvino
Assignee: Drexel University (Philadelphia, PA, US)